Last reviewed · How we verify
NCT05323526
Validation of the Catquest-9SF Questionnaire in Greek Language
trial testing Catquest-9SF questionnaire in Cataract in 100 participants. Completed in 15 December 2021.
15 April 2021
Quick facts
| Lead sponsor | Democritus University of Thrace |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 15 February 2020 |
| Primary completion | 15 April 2021 |
| Estimated completion | 15 December 2021 |
| Sites | 2 locations across Greece |
Drugs / interventions tested
- Catquest-9SF questionnaire
- Demographics and clinical parameters
Conditions studied
- Cataract — all drugs for Cataract →
- Catquest-9SF — all drugs for Catquest-9SF →
Sponsor
Democritus University of Thrace
Who can join
Adults 18 to 85, any sex, with Cataract or Catquest-9SF. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Primary objective of this study is the validation of the Catquest-9SF questionnaire in the Greek population.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Catquest-9SF questionnaire: Validation in a Greek-speaking population using Rasch analysis.
Nanos P, Kouteliari V, Panagiotopoulou EK, Papadopoulos N, et al · · 2022 · cited 2× · PMID 36477289 · DOI 10.1371/journal.pone.0278683
Verify or expand the search:
- PubMed search for NCT05323526
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cataract
Currently open trials in the same condition.
- NCT07301385 — Evaluation of Head-Mounted Spatial Computing and Three-Dimensional (3D) Visualization in Ocular Microsurgery: A Safety a · NA · recruiting
- NCT07462000 — Aqueous Humor and Ocular Tissue Analysis in Glaucoma and Cataract · NA · recruiting
- NCT06891092 — Vivinex Impress XY1-EM vs RayOne EMV · NA · recruiting
- NCT07218796 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting
- NCT07218783 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting
Other Democritus University of Thrace trials
Trials by the same sponsor.
- NCT07077967 — Luminous Efficiency Function V(λ)' of Patients That Underwent Pseudophakic Presbyopic Corrections With EDOF IOLs · recruiting
- NCT07060196 — The Impact of Artificial Lighting on the Visual Capacity of Patients With Age-Related Macular Degeneration · not yet recruiting
- NCT07061431 — In Vitro and in Vivo Evaluation of the Anti-Inflammatory and Antithrombotic Synergy of Vitamin C and Bioflavonoids in He · NA · completed
- NCT07439835 — Evaluation of the Visual Acuity Curves of an Enhanced Monofocal Intraocular Lens · completed
- NCT06460389 — Visual Outcomes After Extended Depth of Focus Intraocular Lens Implantation With and Without Digital Assistance · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05323526 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Democritus University of Thrace
- Last refreshed: 19 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05323526.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing